TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35203045
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (360 µg/d)
Study: 34108169
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice (equivalent dose of telephone-based sessions)
Study: 32544119
Drug: Natural topical
Normalized name: CAPSAICIN 0.025 g in 100 g / LEVOMENTHOL 4 g in 100 g TOPICAL CREAM [XENCARE INFLAMAX NATURAL TOPICAL PAIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural topical skin ointment (aloe vera, honey, and peppermint)
Study: 32743919
Drug: Strength-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength-based intervention (14 weekly group sessions and 2 bi-weekly follow-up calls)
Study: 34791160
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy (including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, statins, mineralocorticoid receptor antagonists, and cardiac rehabilitation)
Study: 32798144
Drug: Combined everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combined everolimus plus lanreotide therapy
Study: 32798144
Drug: Everolimus monotherapy
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus monotherapy
Study: 33296541
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (GCBT) plus usual care (UC)
Study: 33881692
Drug: FYM +
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FYM + P'K' + L
Study: 33881692
Drug: NPK +
Normalized name: LINER,MASK,NASAL REMZZZS#7A-NPK
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPK + L
Study: 32236718
Drug: Concomitant antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant antiplatelet therapy (APT)
Study: 35364018
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg subcutaneously every 4 weeks for 48 weeks
Study: 33376150
Drug: GSK2798745 (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2798745 (2.4 mg)
Study: 33376150
Drug: GSK2798745 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2798745 (5 mg)
Study: 32361032
Drug: Enhanced Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Family Therapy (ET)
Study: 32361032
Drug: Standard cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive behavioral therapy (CBT) family intervention (ST)
Study: 36178519
Drug: Hybrid rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid rapid maxillary expander (RME) and facemask (FM) treatment
Study: 33199379
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg/mL added to LIA mixture
Study: 32441415
Drug: Higher levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher levels of interleukin-1 receptor antagonist (IL-1ra)
Study: 32441415
Drug: Higher levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher levels of interleukin-2 receptor alpha subunit (IL-2rα)
Study: 36134648
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus chemotherapy (S + CT group)
Study: 36134648
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus oral chemotherapy (S + CT group)
Study: 36134648
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus intravenous chemotherapy (S + CT group)
Study: 36134648
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (S + CT group)
Study: 34941035
Drug: Nutritional support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support combined with insulin therapy
Study: 34941035
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (Control)
Study: 32572776
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 mg, daily) and Fuzheng Huayu Tablet (1.6 g, 3 times a day)
Study: 32572776
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 mg, daily) and Fuzheng Huayu Tablet placebo (1.6 g, 3 times a day)
Study: 34522082
Drug: Phenylephrine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine IV bolus (40, 50, 60, 70, or 80 µg)
Study: 34522082
Drug: Phenylephrine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine IV bolus (70 µg)
Study: 34522082
Drug: Phenylephrine IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine IV bolus (60 µg)
Study: 34597388
Drug: Propionic acid
Normalized name: Propionic acid
DrugBank: Propanoic acid (DB03766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionic acid (PA) 500 mg twice daily for 8 weeks
Study: 33549311
Drug: 150 mg/mL
Normalized name: urea 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/mL by PFS × 1 SC injection
Study: 33549311
Drug: 90 mg/mL
Normalized name: urea 390 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/mL by PFS × 2 SC injections
Study: 33549311
Drug: 150 mg/mL
Normalized name: urea 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/mL by AI × 1 SC injection
Study: 33549311
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg SC delivered by PFS or AI
Study: 34602393
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells (MSCs) administered as intravenous infusion of marrow‐derived autologous MSCs (1×10^6 to 2×10^6/kg) for 8 weeks
Study: 34602393
Drug: Acetyl cysteine
Normalized name: Acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl cysteine (NACys) 600mg orally twice a day for 8 weeks
Study: 34517747
Drug: Self-stigma reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-stigma reduction programme (psychoeducation, cognitive behavioural therapy and social skills training)
Study: 34080313
Drug: KMRC011 15
Normalized name: KMRC011, a flagellin-derived radiation countermeasure
DrugBank: Xempritolimod (DB19412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KMRC011 15 μg
Study: 34080313
Drug: KMRC011 20
Normalized name: KMRC011, a flagellin-derived radiation countermeasure
DrugBank: Xempritolimod (DB19412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KMRC011 20 μg
Study: 34080313
Drug: KMRC011 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: KMRC011 (5, 10, 15, and 20 μg)
Study: 34080313
Drug: KMRC011 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: KMRC011 (15 μg and 20 μg)
Study: 34311300
Drug: Paclitaxel (PTX)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (PTX) 100 mg/m2 on days 1, 8, 15, 22, 29 and 36 of each 49-day cycle
Study: 34311300
Drug: Docetaxel (DTX)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (DTX) 70 mg/m2 on day 1 of each 21-day cycle
Study: 32992268
Drug: Experiential training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential training (training‐as‐usual plus a one‐session treatment for fear of spiders)
Study: 35409234
Drug: SSRIs (paroxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (paroxetine or sertraline)
Study: 35870801
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) training curriculum with four 15-minute monthly didactics on BHAG and MI followed by VR simulations.
Study: 34405148
Drug: Collagen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen (40 gr/d) plus Fish Oil (10 ml/d)
Study: 32103410
Drug: STAND (Motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAND (Motivational Interviewing + Behavior Therapy)
Study: 32855218
Drug: Automated closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated closed-loop oxygen administration
Study: 32855218
Drug: Standard manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard manual oxygen administration
Study: 32644867
Drug: Corneal collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal collagen crosslinking with standard antifungal
Study: 32644867
Drug: Standard antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antifungal
Study: 32497491
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable cabotegravir (800 mg given three times at 12 week intervals or 600 mg given five times, administered at one 4 week interval, and every 8 weeks thereafter)
Study: 35247960
Drug: Peer mentorship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer mentorship (weekly telephone calls with trained mentors for 3 months)
Study: 34217844
Drug: Dietary Astragalus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Astragalus Propinquus schischkin polysaccharides (1000 mg/kg)
Study: 34217844
Drug: Dietary Astragalus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary Astragalus Propinquus schischkin polysaccharides (various dosages including 1000 mg/kg)
Study: 32306935
Drug: Cognitive‐behavioural group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural group therapy (CBGT)
Study: 34533410
Drug: Sublingual oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual oestradiol hemihydrate (1.3 mg/day) for 12 weeks
Study: 34533410
Drug: Sublingual oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual oestradiol hemihydrate (1.3 mg/day)
Study: 34502202
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shock wave therapy (LiESWT) at 0.25 mJ/mm2, 3000 pulses, 3 pulses/second
Study: 32326664
Drug: Ubiquinol 200
Normalized name: ubiquinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol 200 mg/day
Study: 32326664
Drug: Ubiquinol 100
Normalized name: ubiquinol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol 100 mg/day
Study: 32326664
Drug: Ubiquinol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol (both doses)
Study: 34800398
Drug: Teriflunomide (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide (14 mg equivalent in adults)
Study: 35709600
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate plus prednisone (1000 mg abiraterone acetate and 10 mg prednisone daily)
Study: 32947028
Drug: Aminolevulinic acid/photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminolevulinic acid/photodynamic therapy
Study: 32947028
Drug: Vehicle/photodynamic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle/photodynamic therapy
Study: 33370247
Drug: Topical oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxygen continuously diffused to DFU tissue
Study: 33370247
Drug: Continuously diffused
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuously diffused topical oxygen
Study: 33175316
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate 0.2% ophthalmic solution
Study: 32051551
Drug: Primary focal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary focal therapy (HIFU or cryotherapy)
Study: 35149036
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with edoxaban (a non-vitamin K antagonist oral anticoagulant)
Study: 35149036
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with edoxaban plus a single antiplatelet agent
Study: 36373820
Drug: 5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/day NWT-03
Study: 36373820
Drug: 5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/day maltodextrin
Study: 33537760
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation at 0.1 g · kg‐1 body weight · d‐1
Study: 32128634
Drug: Trifluridine/tipiracil (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle) plus best supportive care (BSC)
Study: 33837916
Drug: Laboratory sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laboratory sleep monitoring (L)
Study: 34346852
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) data from the Swedish national quality register (Q‐ECT)
Study: 32929647
Drug: HCV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV therapy (interferon-based therapy or interferon-free therapy); duration of treatment not specified, but monitoring period is 6 months for cirrhosis patients and 3 months for non-cirrhosis patients.
Study: 32929647
Drug: HCV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV therapy (treated cohort)
Study: 32929647
Drug: Untreated cohort
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated cohort (therapy-naïve patients)
Study: 33848232
Drug: Combined sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sequential vaccination schedule of IPV and bOPV
Study: 33356044
Drug: Yihechun Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yihechun Capsules (YHC) + Levocarnitine (LC)
Study: 33497514
Drug: Microneedling combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling combined with NB‐UVB phototherapy and topical latanoprost 0.005%
Study: 36237565
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (omeprazole, amoxicillin, and clarithromycin) for 14 days
Study: 36237565
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (omeprazole, amoxicillin, clarithromycin, and metronidazole) for 14 days
Study: 35416973
Drug: Multidose metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidose metronidazole 500 mg twice daily for 7 days
Study: 35416973
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral metronidazole 2 g
Study: 32776828
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 200 mg/week (TEST)
Study: 33273042
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with metformin, pioglitazone, and exenatide
Study: 33273042
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with sequential addition of metformin, glipizide, and insulin
Study: 32506088
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection paracetamol (1gm) and 0.25% bupivacaine (total 20ml) in scalp block
Study: 32506088
Drug: 100ml normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml normal saline infusion and 0.25% bupivacaine (20ml) in scalp block
Study: 34286416
Drug: Interviewer-led telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer-led telephone administration of EORTC QLQ-C30
Study: 34286416
Drug: Paper first
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper first administration of EORTC QLQ-C30
Study: 34286416
Drug: Phone first
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phone first administration of EORTC QLQ-C30
Study: 32307560
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of methylphenidate (N=29)
Study: 32428840
Drug: Hypoenergetic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoenergetic diet with 12 hours of fasting daily
Study: 32126576
Drug: EUS-guided coil
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUS-guided coil embolization and cyanoacrylate injection
Study: 36368940
Drug: PcV 800
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PcV 800 mg × 4 for 5 days
Study: 36368940
Drug: PcV 1
Normalized name: Pneumococcal conjugate PCV 13
Approvals — FDA: no, EMA: no, PMDA: no
Description: PcV 1 g × 3 for 10 days
Study: 35193654
Drug: L-carnitine (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (3000 mg/day for 7 days)
Study: 35193654
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosage and duration as L-carnitine)
Study: 34536308
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with carfilzomib (27-56 mg/sqm) and dexamethasone (20 mg every second week)
Study: 33662112
Drug: Overminus spectacle
Normalized name: econazole nitrate Topical Cream [Spectazole]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overminus spectacle therapy (‐2.50 D for 12 months, then ‐1.25 D for 3 months, followed by nonoverminus spectacles for 3 months)
Study: 35467300
Drug: ω‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 fatty acid immunonutritional therapy
Study: 33939973
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical exercise twice a week
Study: 34538755
Drug: Acebilustat 50
Normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebilustat 50 mg
Study: 34538755
Drug: Acebilustat 100
Normalized name: Acebilustat
DrugBank: Acebilustat (DB15385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebilustat 100 mg
Study: 34538755
Drug: Acebilustat (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebilustat (both doses)
Study: 32865373
Drug: Evolocumab (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (420 mg monthly subcutaneous injections)
Study: 36113007
Drug: Compound betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compound betamethasone
Study: 36113007
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no compound betamethasone)
Study: 36121729
Drug: Novel polymeric
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel polymeric nanoparticle gel
Study: 36121729
Drug: Commercial gel
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial gel (Opalescence PF)
Study: 34546534
Drug: AZD5718 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 (60 mg)
Study: 34546534
Drug: AZD5718 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 (180 mg)
Study: 34546534
Drug: AZD5718 (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 (360 mg)
Study: 34546534
Drug: AZD5718 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5718 (600 mg)
Study: 36440782
Drug: Relatox injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relatox injections
Study: 36059130
Drug: Etonogestrel and
Normalized name: Etonogestrel and Ethinyl Estradiol Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel and Levonorgestrel implants
Study: 34386816
Drug: Vegetable Intervention
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable Intervention (VI) - participants received extra vegetables (≥270 g/d)
Study: 39209438
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (MT)
Study: 35080598
Drug: Taper to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper to placebo (taper group)
Study: 34302145
Drug: Drug repositioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug repositioning approaches
Study: 33244458
Drug: Erlotinib 100
Normalized name: erlotinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 100 mg/d
Study: 35363627
Drug: Erlotinib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 50 mg/d
Study: 34364265
Drug: Yacon flour
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yacon flour (25 g daily)
Study: 32554514
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg plus nab‐paclitaxel 125 mg/m2 and gemcitabine 1,000 mg/m2
Study: 33773565
Drug: Levonorgestrel intrauterine
Normalized name: Levonorgestrel Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel intrauterine system plus metformin (500mg twice daily)
Study: 33574155
Drug: Intravenous acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous acellular sterile filtered amniotic fluid
Study: 35040600
Drug: Adalimumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (5 mg/kg) administered intraperitoneally for 4 weeks
Study: 36106542
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 162 mg every week for 24 weeks
Study: 38985461
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg once daily
Study: 34319510
Drug: UC-MSC treatment
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-MSC treatment (1-2 × 10^6 per kilogram)
Study: 35004547
Drug: Online self-control
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-control training added to multidisciplinary obesity treatment (MOT) program
Study: 35004547
Drug: Sham training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham training added to multidisciplinary obesity treatment (MOT) program
Study: 34308545
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation intervention (88 individual sessions, 45 minutes each, twice per week)